Review Article

You have full text access to this OnlineOpen article

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

  1. Andrew X. Zhu MD, PhD†,*

Article first published online: 26 NOV 2007

DOI: 10.1002/cncr.23175

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 250–259, 15 January 2008

Additional Information

How to Cite

Zhu, A. X. (2008), Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer, 112: 250–259. doi: 10.1002/cncr.23175

Author Information

  1. Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts

  1. †

    Fax: (617) 724-3166.

*Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Lawrence House/P.O. Box 232, 55 Fruit Street, Boston, MA 02114

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 26 NOV 2007
  3. Manuscript Accepted: 24 AUG 2007
  4. Manuscript Received: 6 AUG 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (205K)

REFERENCES

  • 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94: 153–156.
    Direct Link:
  • 2
    El-Serag HB,Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745–750.
  • 3
    El-Serag HB,Davila JA,Petersen NJ,McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003; 139: 817–823.
  • 4
    Thomas MB,Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005; 23: 2892–2899.
  • 5
    Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006; 11: 790–800.
  • 6
    Llovet J,Ricci S,Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract LBA1.
  • 7
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57–70.
  • 8
    Sheu JC. Molecular mechanism of hepatocarcinogenesis J Gastroenterol Hepatol. 1997; 12(9–10): S309–S313.
    Direct Link:
  • 9
    Bergsland EK. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol. 2001; 28: 521–531.
  • 10
    Thorgeirsson SS,Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002; 31: 339–346.
  • 11
    Thomas MB,Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. 2005; 23: 8093–8108.
  • 12
    Miura H,Miyazaki T,Kuroda M, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997; 27: 854–861.
  • 13
    Yamaguchi R,Yano H,Iemura A,Ogasawara S,Haramaki M,Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998; 28: 68–77.
    Direct Link:
  • 14
    Yamaguchi R,Yano H,Nakashima Y, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 2000; 7: 725–729.
  • 15
    Messerini L,Novelli L,Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol. 2004; 57: 867–871.
  • 16
    Chao Y,Li CP,Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003; 10: 355–362.
  • 17
    Jeng KS,Sheen IS,Wang YC, et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 2004; 10: 643–648.
  • 18
    Poon RT,Ho JW,Tong CS,Lau C,Ng IO,Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004; 91: 1354–1360.
    Direct Link:
  • 19
    Carlomagno F,Anaganti S,Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006; 98: 326–334.
  • 20
    Wilhelm SM,Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099–7109.
  • 21
    Liu L,Cao Y,Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851–11858.
  • 22
    Abou-Alfa GK,Schwartz L,Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 4293–4300.
  • 23
    Arora A,Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315: 971–979.
  • 24
    Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002; 38( suppl 5): S3–S10.
  • 25
    Mendel DB,Laird AD,Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327–337.
  • 26
    Murray LJ,Abrams TJ,Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003; 20: 757–766.
  • 27
    Abrams TJ,Murray LJ,Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003; 2: 1011–1021.
  • 28
    Bergers G,Song S,Meyer-Morse N,Bergsland E,Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111: 1287–1295.
  • 29
    Zhu AX,Sahani DV,di Tomaso E, et al. A phase II study ofsunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4637.
  • 30
    Faivre SJ,Raymond E,Douillard JBE, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 3546.
  • 31
    Hurwitz H,Fehrenbacher L,Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–2342.
  • 32
    Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987–989.
  • 33
    Willett CG,Boucher Y,di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145–147.
  • 34
    Schwartz JD,Schwartz M,Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol (Meeting Abstracts). 2006; 24(18S). Abstract 4144.
  • 35
    Malka D,Dromain C,Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4570.
  • 36
    Zhu AX,Blaszkowsky LS,Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 1898–1903.
  • 37
    Sun W,Haller DG,Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4574.
  • 38
    Hsu C,Yang T,Hsu C, et al. Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 15190.
  • 39
    Thomas MB,Chadha R,Iwasaki M,Glover K,Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4567.
  • 40
    Wedge SR,Kendrew J,Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65: 4389–4400.
  • 41
    Alberts SR,Morlan BW,Kim GP, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)–interim review of toxicity. 2007 Gastrointestinal Cancer Symposium, Orlando, Fla, January 19–21, 2007. Abstract 186.
  • 42
    Wood JM. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina. 2000; 60( suppl 2): 41–47.
  • 43
    Drevs J,Muller-Driver R,Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002; 62: 4015–4022.
  • 44
    Koch I,Baron A,Roberts S, et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts). 2005; 23(16S, pt I of II). Abstract 4134.
  • 45
    Kira S,Nakanishi T,Suemori S,Kitamoto M,Watanabe Y,Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997; 17: 177–182.
  • 46
    Kiss A,Wang NJ,Xie JP,Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res. 1997; 3: 1059–1066.
  • 47
    Harada K,Shiota G,Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999; 19: 318–325.
    Direct Link:
  • 48
    Ito Y,Takeda T,Higashiyama S, et al. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep. 2001; 8: 903–907.
  • 49
    Carlin CR,Simon D,Mattison J,Knowles BB. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol. 1988; 8: 25–34.
  • 50
    Yeh YC,Tsai JF,Chuang LY, et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987; 47: 896–901.
  • 51
    Morimitsu Y,Hsia CC,Kojiro M,Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol. 1995; 26: 1126–1132.
  • 52
    Yamaguchi K,Carr BI,Nalesnik MA. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol. 1995; 58: 240–245.
    Direct Link:
  • 53
    Philip PA,Mahoney MR,Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005; 23: 6657–6663.
  • 54
    Thomas MB,Chadha R,Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007; 110: 1059–1067.
    Direct Link:
  • 55
    O'Dwyer PJ,Giantonio BJ,Levy DE,Kauh JS,Fitzgerald DB,Benson ABIII. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol (Meeting Abstracts). 2006; 24(18S). Abstract 4143.
  • 56
    Ramanathan RK,Belani CP,Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol (Meeting Abstracts). 2006; 24(18S). Abstract 4010.
  • 57
    Zhu AX,Stuart K,Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007; 110: 581–589.
    Direct Link:
  • 58
    Gruenwald V,Wilkens L,Gebel M, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4598.
  • 59
    Louafi S,Hebbar M,Rosmorduc O, et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. J Clin Oncol (Meeting Abstracts). 2007; 25(18S). Abstract 4594.
View Full Article (HTML) Get PDF (205K)